No Data
No Data
ProKidney Phase 2 Trial Success Sparks Investor Interest
ProKidney to Participate in the Jefferies Global Healthcare Conference
WINSTON-SALEM, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced
ProKidney Is Maintained at Neutral by B of A Securities
ProKidney Is Maintained at Neutral by B of A Securities
B of A Securities Maintains Neutral on ProKidney, Raises Price Target to $4
B of A Securities analyst Jason Gerberry maintains ProKidney (NASDAQ:PROK) with a Neutral and raises the price target from $3 to $4.
ProKidney Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/29/2024 2.86% B of A Securities $3 → $4 Maintains Neutral 03/07/2024 -22.86% Morgan Stanley → $3 Assume
Buy Rating Affirmed for ProKidney on Rilparencel's Promising Efficacy in CKD Treatment
No Data